HB Wealth Management LLC increased its position in Eli Lilly and Company (NYSE:LLY – Get Rating) by 3.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 15,423 shares of the company’s stock after acquiring an additional 500 shares during the quarter. HB Wealth Management LLC’s holdings in Eli Lilly and were worth $5,001,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the company. Cordant Inc. purchased a new position in Eli Lilly and during the 1st quarter valued at about $25,000. Icapital Wealth LLC purchased a new position in Eli Lilly and during the 1st quarter valued at about $28,000. HWG Holdings LP purchased a new position in Eli Lilly and during the 4th quarter valued at about $28,000. Oliver Lagore Vanvalin Investment Group purchased a new position in Eli Lilly and during the 1st quarter valued at about $33,000. Finally, Selective Wealth Management Inc. purchased a new position in Eli Lilly and during the 1st quarter valued at about $33,000. Hedge funds and other institutional investors own 82.45% of the company’s stock.
Insiders Place Their Bets
In other news, Director Jackson P. Tai bought 656 shares of the firm’s stock in a transaction on Friday, August 12th. The stock was acquired at an average cost of $304.19 per share, with a total value of $199,548.64. Following the completion of the acquisition, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Jackson P. Tai acquired 656 shares of Eli Lilly and stock in a transaction dated Friday, August 12th. The stock was purchased at an average cost of $304.19 per share, for a total transaction of $199,548.64. Following the purchase, the director now directly owns 62,857 shares of the company’s stock, valued at approximately $19,120,470.83. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 41,857 shares of the stock in a transaction on Monday, June 27th. The stock was sold at an average price of $329.05, for a total value of $13,773,045.85. Following the completion of the sale, the insider now owns 104,161,953 shares of the company’s stock, valued at approximately $34,274,490,634.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 328,125 shares of company stock valued at $108,581,151. Insiders own 0.12% of the company’s stock.
Eli Lilly and Stock Down 0.5 %
Eli Lilly and (NYSE:LLY – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. During the same period last year, the business earned $1.87 earnings per share. The company’s revenue was down 3.7% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.
Eli Lilly and Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were issued a $0.98 dividend. The ex-dividend date of this dividend was Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.27%. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.
Wall Street Analyst Weigh In
LLY has been the subject of a number of research analyst reports. Barclays lifted their price target on Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, July 7th. BMO Capital Markets lifted their price target on Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research report on Tuesday, September 6th. StockNews.com upgraded Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 14th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Finally, Morgan Stanley lifted their price target on Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a research report on Wednesday, September 7th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $332.19.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.